InMed Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
InMed Pharmaceuticals has a total shareholder equity of $8.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $10.5M and $2.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$5.63m |
| Equity | US$8.40m |
| Total liabilities | US$2.07m |
| Total assets | US$10.47m |
Recent financial health updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02Financial Position Analysis
Short Term Liabilities: INM's short term assets ($7.3M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: INM's short term assets ($7.3M) exceed its long term liabilities ($633.8K).
Debt to Equity History and Analysis
Debt Level: INM is debt free.
Reducing Debt: INM had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: INM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 6.6% each year